KEAP1 and non-small cell lung carcinoma: This study demonstrates the potential effect of KEAP1 mutation on tumor immune milieu of LUAD subtype of NSCLC patients, highlighting the potential efficacies of the immunotherapy treatment using PD‐L1 blockers in KEAP1‐wild type LUADs.